MiRNA-489 in treatment of breast cancer
Breast cancer treatment methods and materials incorporating microRNA-489 are described. The methods and materials have been developed from identification of a double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis. The methods and materials may be particularly beneficial in treatment and diagnosis of HER2 positive breast cancers.
1. A method for decreasing breast cancer cell proliferation, the method comprising:
determining in a breast cancer cell population the over-expression of one or more of SHP2, ERK, and p-ERK; and
thereafter, delivering a polynucleotide to the population of breast cancer cells, the polynucleotide comprising a microRNA-489 or a microRNA-489 mimic, or encoding the microRNA-489 or the microRNA-489 mimic, wherein following the delivery of the polynucleotide, the breast cancer cells exhibit a decrease in proliferation rate.
2. The method of claim 1 , wherein the polynucleotide is a DNA sequence.
3. The method of claim 2 , wherein the polynucleotide is delivered in conjunction with an expression system.
4. The method of claim 2 , the polynucleotide comprising SEQ ID NO: 1.
5. The method of claim 1 , wherein the polynucleotide is an RNA sequence.
6. The method of claim 5 , wherein the RNA sequence comprises a pri-miRNA-489, a pre-miRNA-489, or a mature single strand miRNA-489.
7. The method of claim 5 , the polynucleotide comprising SEQ ID NO: 2.
8. The method of claim 1 , wherein the breast cancer cells are also determined to over-express HER2.
9. The method of claim 1 , wherein the polynucleotide is the microRNA-489 mimic.
10. The method of claim 1 , wherein the method comprises an in vivo delivery of the polynucleotide to the population of breast cancer cells.
11. The method of claim 1 , wherein the method comprises an ex vivo delivery of the polynucleotide to the population of breast cancer cells.
12. The method of claim 1 , wherein the method comprises an in vitro delivery of the polynucleotide to the population of breast cancer cells.
13. The method of claim 1 , wherein the polynucleotide is delivered as a component of a transgenic cell.
14. The method of claim 1 , wherein the polynucleotide is delivered within a delivery vehicle.
15. The method of claim 14 , wherein the delivery vehicle comprises a micro- or nano-sized vesicle.
16. The method of claim 1 , further comprising prior to the delivery of the polynucleotide to the population of breast cancer cells, obtaining a sample from a subject and determining the ratio of microRNA-489 concentration to HER2 concentration in the sample.